On-line	Table	1.	<b>Procedural</b>	and	follow-up	analysis
OII-IIIIC	IUDIC		i i occuui ai	ullu	IUIIUVV-up	ununyono

	No	0/	No. of Articles Providing
	No.	%	These Data
Demographics			
Patients with stent deployed	1457		37
Aneurysms stented	1510	0.0	37
% patients stent deployment failed		3.6	35
Aneurysms treated with Neuroform 1, 2 and Treo stents	1017	67.4	37
Aneurysms s/p subarachnoid hemorrhage	323	22.2	37
Large aneurysms (>10 mm in most studies)	151	28.4	23
Giant aneurysms (>25 mm in all studies)	59	8.8	24
Total complications	280	19.2	37
Death	30	2.1	37
Thromboembolic complications	119	9.6	36
Death	7	0.6	36
Hemorrhagic complications	27	2.2	36
Death	11	0.9	36
Technical coil complications	18	1.9	35
Death	0	0.0	35
Other complications (eg, groin issues, mass effect, infection)	87	7.0	36
Death	2	0.2	36
Stent-related technical complications	92	9.3	35
Stent not delivered	42	4.2	35
Stent problems other than delivery (eg, migration, detachment issues, navigation difficulty)	50	5.0	35
Aneurysms fully occluded at treatment conclusion Follow-up: imaging	523	45.5	32
Patients followed up by imaging	695		23
Average duration of follow-up	13		20
Median duration of follow-up (mo)	6		17
Complete occlusion on follow-up	424	61.0	23
Complete occlusion of previously incompletely occluded aneurysm	91	22.5	23 18
Recanalization of aneurysms initially graded as completely occluded on follow-up	93 62	14.0	22 19
Retreated aneurysms		12.9	• •
In-stent stenosis	24	3.5	20
Clinically symptomatic in-stent stenosis	4	16.7	20
Time to in-stent stenosis, average (mo)	5	0.0	19
Stent occlusion	4	0.6	19
Clinically symptomatic in-stent occlusion	1	25.0	19
Time to occlusion, average (mo)	8		19
Follow-up: clinical			
No. patients with clinical follow-up	736		27
Average clinical follow-up (mo)	13		25
Median clinical follow-up (mo)	6		21
Follow-up death	4	0.7	22
Follow-up TIA or stroke in the relevant brain territory	21	3.2	23
Average time to TIA or stroke (mo)	1		22

Note:-s/p indicates status-post